Potential for novel MUC1 glycopeptide-specific antibody in passive cancer immunotherapy

Caroline Benedicte Kjærulff Mathiesen, Hans H. Wandall, Anders Elm Pedersen

Publikation: Bidrag til tidsskriftTidsskriftsartikelForskningpeer review

Abstract

MUC1 is an important target for antibodies in passive cancer immunotherapy. Antibodies against mucin glycans or mucin peptide backbone alone may give rise to cross reactivity with normal tissues. Therefore, attempts to identify antibodies against cancer-specific MUC1 glycopeptide epitopes havebeen made. We recently demonstrated that a monoclonal antibody against the immunodominant Tn-MUC1 (GalNAc-α-MUC1) antigen induced ADCC in breast cancer cell lines, suggesting the feasibility of targeting combined glycopeptide epitopes in future passive cancer immunotherapy.
OriginalsprogEngelsk
Artikelnummer24063621
TidsskriftImmunopharmacology and Immunotoxicology
Vol/bind35
Udgave nummer6
Sider (fra-til)649-652
Antal sider13
ISSN0892-3973
DOI
StatusUdgivet - 2013
Udgivet eksterntJa

Emneord

  • Kliniske undersøgelsesmetoder, laboratorieteknologi og radiografi

Citationsformater